Dallas, Texas (September 9, 2011) – StockGuru Shines its Spotlight on ChromaDex® Corp. (OTCBB: CDXC) announced yesterday that the University of California, Irvine has granted ChromaDex® the exclusive rights to a joint patent application filed by ChromaDex® and the university for the method of inducing UDP-glucuronosyltransferase (UGT) activity using pTeroPure®, ChromaDex®’s ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits. UGT is an enzyme responsible for the process of glucuronidation, which changes unwanted compounds in to a more water-soluble version, thus allowing for easier elimination from the body. It is known that UGTs prevent melanoma invasiveness by eliminating toxic compounds and are subsequently lost during melanoma progression.  The Company traded down, closing at $1.04, near its fifty-two week low.

With more than 3.5 million skin cancers diagnosed in more than two million people annually,(1) data shows that there has been at least a 300 percent increase in skin cancer incidence since 1994.(2) Researchers believe that pTeroPure® may show promise for the regression of precancerous diseases such as actinic keratoses (AK) and other changes that are associated with photodamage of the skin. AKs are the earliest identifiable lesions that can eventually develop into skin cancer. These lesions are diagnosed in 14 percent of all visits to dermatologists, following only acne and dermatitis in frequency according to the American Academy of Dermatology.

The pterostilbene-based pTeroPure® may also be used to suppress or prevent progression of these precancerous diseases to non-melanoma skin cancer (NMSC). In prior studies, pterostilbene has been shown to inhibit melanoma cell growth, although the mechanism of action is still being determined.(3)

“As we continue to build on our strategy of increasing intellectual property with our proprietary ingredients, we also strive to provide solutions to increase quality of life,” said Frank L. Jaksch, Jr., CEO of ChromaDex®. “Adding this patent to our portfolio reinforces ChromaDex®’s commitment to bringing science-based solutions to the market.”

“Our research to evaluate pterostilbene’s effectiveness in the prevention and treatment of skin damage and cancers will potentially offer medical professionals and patients alike a new approach in battling the devastating effects of diseases like melanoma and other skin cancers,” said Frank Meyskens, MD, Director of the Chao Family Comprehensive Cancer Center, University of California, Irvine.

“For over 11 years, ChromaDex® has been committed to the discovery and development of ingredients that promote health and well-being,” said William Spengler, President of ChromaDex®. “We are now uniquely positioned to enter a potentially very large but underserved segment of the skincare market with our novel ingredient pTeroPure®.”

About ChromaDex®

ChromaDex® is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.

ChromaDex® Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

(1) Rogers, HW, Weinstock, MA, Harris, AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146(3):283-287.

(2) The Skin Cancer Foundation: http://www.skincancer.org/nonmelanoma-skin-cancer-incidence-jumps-by-over-300-percent.html. Accessed August 31, 2011.

(3) Schneider JG, Alosi JA, McDonald DE, McFadden DW. Effects of pterostilbene on melanoma alone and in synergy with inositol hexaphosphate. Am J Surg 2010; 198:679-684.

 

To view this StockGuru Spotlight, please visit: http://stockguru.com/category/latest-spotlights/

To get free alerts on this and other similar stocks, please register here:

Get StockGuru Email Alerts

What is the StockGuru Spotlight?

Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.

StockGuru looks for potential break-out candidates in The StockGuru Spotlight.  Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage.  There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below.   StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.

To feature a company in The StockGuru Spotlight please contact the Publisher at [email protected].  If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact the StockGuru Publisher John Pentony at this email address:  [email protected].

Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions.  SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage.  When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present.  Additionally SG also discloses any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

John Pentony, Publisher, Stockguru.com

Tel: +1 469 252 3031

e-mail: [email protected]